RRx-001 is an anti-cancer immunotherapeutic that increases the sensitivity of drug resistant tumors via multiple mechanisms which involve binding to hemoglobin and enhancing nitrite reductase activity of deoxyhemoglobin.
OBJECTIVE:
In the present study, the effect of clinically used doses of RRx-001 on erythrocyte deformability was examined.
METHODS:
A dose dependent effect of RRx-001 (1-1000 micro molar) on erythrocyte deformability was measured by ektacytometer under hypoxia (n = 8). Low dose RRx-001 (20 micro molar) in the presence of ODQ (1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one), L-NAME (L-NG-Nitroarginine methyl ester) or nitrite were examined both in normoxia and hypoxia. Intracellular nitric oxide (NO) levels were measured fluorometrically with DAF-FM-DA.
RESULTS:
Higher doses of RRx-001 (100, 1000 micro molar) significantly decreased erythrocyte deformability under hypoxia (p < 0.01; p < 0.05, respectively). RRx-001 (20 micro molar), alone or in combination with ODQ or L-NAME, did not change deformability. However, RRx-001 and nitrite caused an increase in deformability (p < 0.01) under hypoxia. RRx-001 induced NO production was more pronounced in the presence of nitrite (p < 0.05).
CONCLUSIONS:
Co-administration of RRx-001 and nitrite under hypoxic conditions results in a significant increase in erythrocyte deformability that is related to increased NO production. We suggest that measurement of serum nitrite level in RRx-001 treated cancer patients should be routinely undertaken and supplemented if levels are low for maximal activity.
OronskyBScicinskiJNingSPeehlDOronskyACabralesPRRx-001, A novel dinitroazetidine radiosensitizer. Invest New Drugs. 2016;34(3):371–377.
2.
OronskyBReidTRLarsonCCarterCABrzezniakCEOronskyARRx-001 protects against cisplatin-induced toxicities. J Cancer Res Clin Oncol. 2017;143(9):1671–1677. doi:10.1007/s00432-017-2416-4.
3.
ScicinskiJFisherGCarterCCho-PhanCKunzPNingSThe development of RRx-001, a novel nitric-oxide-mediated epigenetically active anticancer agent. Redox Biol. 2015;5:422.
4.
ScicinskiJOronskyBNingSKnoxSPeehlDKimMMNO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biol. 2015;6:1–8.
5.
ReidTOronskyBScicinskiJScribnerCLKnoxSJNingSSafety and activity of RRx-001 in patients with advanced cancer: A first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015;16(9):1133–1142.
6.
BrzezniakCOronskyBScicinskiJCaroenSCabralesPDean AbroukNConversion of platinum-etoposide-resistant to sensitive SCLC after treatment with the Epi-Immunotherapeutic RRx-001: A case report. Oncol Res Treat. 2016;39(11):720–723.
7.
OronskyBCaroenSZemanKQuinnMBrzezniakCScicinskiJA partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001. Clin Med Insights Oncol. 2016;10:105–108.
8.
CarterCAOronskyBCaroenSScicinskiJDegesysACabralesPPartial response in an RRx-001-primed patient with refractory small-cell lung cancer after a third introduction of platinum doublets. Case Rep Oncol. 2016;9(2):285–289.
9.
CarterCAOronskyBTCaroenSZScicinskiJJCabralesPReidTPartial response to platinum doublets in refractory EGFR-positive non-small cell lung cancer patients after RRx-001: Evidence of episensitization. Case Rep Oncol. 2016;9(1):62–67.
10.
BrzezniakCSchmitzBAPetersonPGDegesysAOronskyBTScicinskiJJRRx-001-induced tumor necrosis and immune cell infiltration in an EGFR mutation-positive NSCLC with resistance to EGFR tyrosine kinase inhibitors: A case report. Case Rep Oncol. 2016;9(1):45–50.
11.
DasDSRayADasASongYTianZOronskyBA novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016;30(11):2187–2197.
12.
ReidTDadSKornROronskyBKnoxSScicinskiJ. Two case reports of resensitization to previous chemotherapy with the novel hypoxia-activated hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer patients. Case Rep Oncol. 2014;7(1):79–85.
13.
KimMMParmarHCaoYPramanikPSchipperMHaymanJWhole brain radiotherapy and RRx-001: Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A TITE-CRM phase I/II clinical trial. Transl Oncol. 2016;9(2):108–113.
14.
CarterCADegesysAOronskyBScicinskiJCaroenSZOronskyALFlushing out carcinoid syndrome: Beneficial effect of the anticancer epigenetic agent RRx-001 in a patient with a treatment-refractory neuroendocrine tumor. Case Rep Oncol. 2015;8(3):461–465.
15.
ScicinskiJOronskyBTaylorMLuoGMusickTMariniJPreclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab Dispos. 2012;40(9):1810–1816.
16.
OronskyBOronskyNCabralesP. Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001. J Cell Mol Med. 2018;22(10):5076–5082. doi:10.1111/jcmm.13791.
17.
NingSBednarskiMOronskyBScicinskiJSaulGKnoxSJ. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012;72(10):2600–2608.
18.
FensMHCabralesPScicinskiJLarkinSKSuhJHKuypersFATargeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: A superagonist of nitric oxide generation. Med Oncol. 2016;33(8):85.
19.
OronskyBScicinskiJNingSPeehlDOronskyACabralesPRockets, radiosensitizers, and RRx-001: An origin story part I. Discov Med. 2016;21(115):173–180.
CosbyKPartoviKSCrawfordJHPatelRPReiterCDMartyrSNitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9:1498–1505.
25.
Bor-KucukatayMWenbyRBMeiselmanHJBaskurtOK. Effects of nitric oxide on red blood cell deformability. Am J Physiol Heart Circ Physiol. 2003;284(5):H1577–H1584.
26.
BarodkaVMohantyJGMustafaAKSanthanamLNyhanABhuniaAKNitroprusside inhibits calcium-induced impairment of red blood cell deformability. Transfusion. 2014;54(2):434–444.
27.
BelangerAMKeggiCKaniasTGladwinMTKim-ShapiroDB. Effects of nitric oxide and its congeners on sickle red blood cell deformability. Transfusion. 2015;55(10):2464–2472.
28.
MesquitaRPiresISaldanhaCMartins-SilvaJ. Effects of acetylcholine and spermineNONOate on erythrocyte hemorheologic and oxygen carrying properties. Clin Hemorheol Microcirc. 2001;25(3-4):153–163.
29.
StepuroTLZinchukVV. Nitric oxide effect on the hemoglobin-oxygen affinity. J Physiol Pharmacol. 2006;57(1):29–38.
30.
YalcinOOronskyBCarvalhoLJKuypersFAScicinskiJCabralesP. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malar J. 2015;14:218.
31.
BaskurtOKHardemanMRUyukluMUlkerPCengizMNemethNParameterization of red blood cell elongation index–shear stress curves obtained by ektacytometry. Scand J Clin Lab Invest. 2009;69(7):777–788.
32.
Cortese-KrottMMRodriguez-MateosAKuhnleGGBrownGFeelischMKelmM. A multilevel analytical approach for detection and visualization of intracellular NO production and nitrosation events using diaminofluoresceins. Free Radic Biol Med. 2012;53(11):2146–2158.
33.
OronskyBTKnoxSJScicinskiJ. Six degrees of separation: The oxygen effect in the development of radiosensitizers. Transl Oncol. 2011;4(4):189–198.
34.
OronskyBTKnoxSJScicinskiJJ. Is Nitric Oxide (NO) the last word in radiosensitization? a review. Transl Oncol. 2012;5(2):66–71.
35.
JordanBFBegheinNAubryMGrégoireVGallezB. Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors. Int J Cancer. 2003;103(1):138–141.
36.
ThewsOKelleherDKVaupelP. No improvement in perfusion and oxygenation of experimental tumors upon application of vasodilator drugs. Int J Oncol. 2001;19(6):1243–1247.
37.
ShanSQRosnerGLBraunRDHahnJPearceCDewhirstMW. Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br J Cancer. 1997;76(4):429–437.
38.
GuoSAshinaMOlesenJBirkS. The effect of sodium nitroprusside on cerebral hemodynamics and headache in healthy subjects. Cephalalgia. 2013;33(5):301–307.
39.
EllsworthMLForresterTEllisCGDietrichHH. The erythrocyte as a regulator of vascular tone. Am J Physiol. 1995;269(6):H2155–61.
KorbutRGryglewskiRJ. Nitric oxide from polymorphonuclear leukocytes modulates red blood cell deformability in vitro. Eur J Pharmacol. 1993;234:17–22.
42.
SuhrFBrenigJMullerRBehrensHBlochWGrauM. Moderate exercise promotes human RBC-NOS activity, NO production and deformability through Akt kinase pathway. PLoS One. 2012;7(9):e45982.
43.
StarzykDKorbutRGryglewskiRJ. The role of nitric oxide in regulation of deformability of red blood cells in acute phase of endotoxaemia in rats. J Physiol Pharmacol. 1997;48:731–735.
44.
GrauMLautenAHoeppenerSGoebelBBrenigJJungCRegulation of red blood cell deformability is independent of red blood cell-nitric oxide synthase under hypoxia. Clin Hemorheol Microcirc. 2016;63(3):199–215.
45.
OronskyB. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells. Discov Med. 2016;21(116):251–265.
46.
CoccoP. Does G6PD deficiency protect against cancer? A critical review. J Epidemiol Community Health. 1987;41(2):89–93.
47.
TangHYHoHYWuPRChenSHKuypersFAChengMLInability to maintain GSH pool in G6PD-deficient red cells causes futile AMPK activation and irreversible metabolic disturbance. Antioxid Redox Signal. 2015;22:744–759.
48.
JohnsonRMPanchoosinghHGoyetteG JrRavindranathY. Increased erythrocyte deformability in fetal erythropoiesis and in erythrocytes deficient in glucose-6-phosphate dehydrogenase and other glycolytic enzymes. Pediatric Research. 1999;45(1):106–113.
49.
GurbuzNYalcinOAksuTBaskurtO. The Relationship between the enzyme activity, lipid peroxidation and red blood cells deformability in hemizygous and heterozygous glucose-6-phosphate dehydrogenase deficient individuals. Clin Hemorheol Microcirc. 2004;31:235–242.
50.
CabralesPScicinskiJReidTKuypersFLarkinSFensMA look inside the mechanistic black box: Are red blood cells the critical effectors of RRx001 cytotoxicity?. Med Oncol. 2016;33(7):63.
51.
BalazyMKaminskiPMMaoKTanJWolinMS. S-Nitroglutathione, a product of the reaction between peroxynitrite and glutathione that generates nitric oxide. J Biol Chem. 1998;273:32009–32015.
AndersonMEMeisterA. Dynamic state of glutathione in blood plasma. J Biol Chem. 1980;255:9530–9533.
54.
MinamiyamaYTakemuraSInoueM. Effect of thiol status on nitric oxide metabolism in the circulation. Arch Biochem Biophys. 1997;341:186–192.
55.
BelderAJMacAllisterRRadomskiMWMoncadaSVallancePJ. Effects of S-nitroso-glutathione in the human forearm circulation: Evidence for selective inhibition of platelet activation. Cardiovasc Res. 1994;28:691–694.
56.
RamsayBRadomskiMDe BelderAMartinJFLopez-JaramilloP. Systemic effects of S-nitroso-glutathione in the human following intravenous infusion. Br J Clin Pharmacol. 1995;40:101–102.
57.
WardmanP. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol). 2007;19:397–417.
58.
GladwinMT. Nitrite as an intrinsic signaling molecule. Nat Chem Biol. 2005(1):245–246.
59.
CrawfordJHIsbellTSHuangZShivaSChackoBKHypoxia, red blood cells and nitrite regulate NO-dependent hypoxic vasodilation. Blood. 2006;107:566–574.
60.
BinkerdEFKolariOE. The history and use of nitrate and nitrite in the curing of meat. Food Cosmet Toxicol. 1975;13(6):655–661.
